DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
All previous objections and rejections not reiterated herein were overcome by claim amendments, filed December 9th, 2024, that have been fully considered and found persuasive. As such all objections and rejections not reiterated herein have been withdrawn.
Claim Objections
Claim 1 is objected to because of the following informalities: missing the word “form”. Claim 1 recites, in line 4, the limitation where “R5 and R6 together may a 3 to 7-member cycloalkyl ring”; however, claim 1 should recite,” should recite “R5 and R6 together may form a 3 to 7-member cycloalkyl ring”. Appropriate correction is required.
Claim 7 is objected to because of the following informalities: missing the word “form”. Claim 7 recites, in lines 10 – 11, the limitation where “R5 and R6 together may a 3 to 7-member cycloalkyl ring”; however, claim 1 should recite,” should recite “R5 and R6 together may form a 3 to 7-member cycloalkyl ring”. Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 20 – 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding claim 20, the phrase "such as" in line 2 of the claim renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). As a consequence, one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Specifically one of ordinary skill in the art would not be reasonably apprised of where the limitation after the “such as,” is required or not. Therefore, given the uncertainty around the limitations after the “such as,” claim 20 is rejected under 35 U.S.C. 112(b).
Regarding claim 21, the phrase "such as" in line 2 of the claim renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). As a consequence, one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Specifically one of ordinary skill in the art would not be reasonably apprised of where the limitation after the “such as,” is required or not. Therefore, given the uncertainty around the limitations after the “such as,” claim 21 is rejected under 35 U.S.C. 112(b).
Discussion of the prior art
The closest prior art of Tokumitsu et. al. ((2002), STO-609, a Specific Inhibitor of the Ca2+/Calmodulin-dependent Protein Kinase Kinase, Journal of Biological Chemistry, 18, 15813-15818) teach compound STO-609 of structure
PNG
media_image1.png
200
400
media_image1.png
Greyscale
where X = O; Y = CR5R6 where R5 and R6 come together to form a phenyl; R1 = -COOH; and R2 = R3 = H. See page 15814.
However, the prior art of Tokumitsu et. al. fail to teach a compound having the Formula (XX)
PNG
media_image2.png
344
142
media_image2.png
Greyscale
where R5 and R6 are independently hydrogen (H), C1-C5 alkyl, or R5 and R6 together may a 3 to 7-member cycloalkyl ring. See claim 1 limitation. Moreover, the prior art of Tokumitsu et. al. fail to teach a compound having the Formula (XXI)
PNG
media_image3.png
358
176
media_image3.png
Greyscale
. See claim 7 limitation. Now while the prior art compound STO-609 has a ring; the ring of STO-609 is an aromatic ring which is unsaturated, that is does not have the maximum number of H atoms, and contains double bonds. Whereas the compound species of claims 1 and 7 where R5 and R6 come together to form a 3 to 7-member cycloalkyl ring is saturated ring system, containing no double bonds and having the maximum number of H atoms. Moreover, it is well understood in the chemical arts that there is differences in the chemical and physical properties between saturated and unsaturated ring systems. As a consequence of the above difference the ring system of STO-609 does not render obvious compound species of claims 1 and 7 where R5 and R6 come together to form a 3 to 7-member cycloalkyl ring. Thus the closest prior art teaching of STO-609 by Tokumitsu et. al. fails to anticipate and render obvious the compounds of claims 1- 5, 7 – 11; thus claims 1 – 5, and 7 – 11 are free of the prior art. Moreover claims 12 – 19 which direct to method comprising administering the compounds of either claim 1 or 7 are free of the prior art.
Additionally, the prior art of Racioppi et. al. ((2012), Calcium/Calmodulin-dependent Protein Kinase Kinase 2: Roles in Signaling and Pathophysiology Journal of Biological Chemistry, 287, 31658-31665) teach that Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is involved in regulating many important physiological and pathophysiological processes, including energy balance, adiposity, glucose homeostasis, hematopoiesis, inflammation, and cancer. See page 31658 Abstract. Moreover, specification, is enabled for the modulation of CaMKK2 activity in vitro and in vivo. See specification pages 31 – 34 Examples 2 – 5. Thus the methods of claims 12 – 19 are enabled.
Given the teachings of Racioppi et. al. the method claims of
Conclusion
Claims 20 – 21 are rejected. Claims 1 – 5, and 7 – 19 are objected.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAWANNA S WHITE whose telephone number is (703)756-4687. The examiner can normally be reached 7:00 am - 5:00 pm [EST] M - Th.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DAWANNA SHAR-DAY WHITE/Examiner, Art Unit 1627